HONOLULU — At the Association for Research in Vision and Ophthalmology meeting here, Carolyn Pan, MD, discusses post hoc analysis of the RADIANCE trial, in which safety and efficacy of Lucentis (ranibizumab, Genentech) was compared with verteporfin photodynamic therapy for treatment of myopic choroidal neovascularization.
Original Article: VIDEO: Researcher discusses post hoc analysis of RADIANCE trial